Clozapine and Covid-19 – What should Psychiatrists Know?
Clozapine and COVID:
Clozapine is associated with neutropenia and agranulocytosis.
Patients with COVID-19 may have reduced blood counts that can impact on the ongoing prescribing of clozapine.
The Australian Commission on Safety and Quality in Healthcare position statement suggests that during the COVID-19 pandemic, to ensure uninterrupted supply of clozapine:
The frequency of Absolute Neutrophil Count (ANC) monitoring may be reduced to every 3 months for people fulfilling all of the following criteria:
- Continuous clozapine treatment for >1 year
- Have never had an ANC <2000/μl (or <1500/μl if patient has a history of benign ethnic neutropenia)
- No safe or practical access to ANC testing